For decades, individuals living with chronic suicidal thoughts have remained largely invisible in psychiatric research. This pattern has continued into the new era of psychedelic research.
While studies of psilocybin and other psychedelic compounds have produced promising results for treatment-resistant depression, post-traumatic stress disorder, and substance use disorders, patients experiencing chronic suicidal ideation have historically been excluded from clinical trials due to safety concerns.
Researchers at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics set out to change that.
Their recently published study, “Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial,” represents one of the first investigations of psilocybin in this highly vulnerable population. The results were striking: Approximately two-thirds of participants experienced rapid, substantial, and durable reductions in both suicidal ideation and depressive symptoms that persisted through 12 weeks after a single dose of synthetic psilocybin.
For Scott Aaronson, MD, Sheppard Pratt chief science officer and leader of the Institute for Advanced Diagnostics and Therapeutics, the findings reflect a broader shift underway in psychiatry.
“We are looking at treatments that can produce meaningful change within hours,” he says. “Some participants leave the dosing session already feeling significantly different than when they arrived.”
Opening a New Window for Change
Traditional antidepressants often require weeks to take effect and may provide limited benefit for individuals with severe or treatment-resistant symptoms. Psychedelics appear to work differently.
Rather than functioning as conventional antidepressants, Aaronson describes psychedelic compounds as creating a temporary state of increased neural connectivity and psychological flexibility—a window during which lasting change becomes possible.
“What psychedelics seem to do is open a door,” he explains. “The question then becomes how we help patients walk through it.”
That question is driving much of the next generation of psychedelic research.
While regulatory studies have understandably focused on demonstrating the safety and effectiveness of the compounds themselves, Aaronson and Jeff LaPratt, PsyD, believe the future lies in understanding how psychedelic treatments can be integrated into broader, personalized treatment plans.
Beyond Treatment-Resistant Depression
The field’s earliest successes focused largely on treatment-resistant depression, but researchers are increasingly exploring a wider range of psychiatric conditions.
Aaronson notes that many of the disorders being studied share a common characteristic: psychological rigidity.
“Depression, PTSD, obsessive-compulsive disorder, substance use disorders—these are all conditions where people become stuck in patterns of thinking, feeling, or behavior,” he says. “Psychedelics may help loosen that rigidity and create opportunities for change.”
At Sheppard Pratt, investigators have already contributed to research involving bipolar type II depression, chronic suicidal ideation, and eating disorders, while additional studies continue to examine anxiety and depression using compounds such as LSD. Yet both Aaronson and LaPratt emphasize that the compound itself is only part of the story.
Why Context Matters
One of the most important lessons emerging from psychedelic research is that treatment outcomes are shaped not only by the medication but also by preparation, support, and integration.
“The star of the show isn’t necessarily the psychedelic,” says LaPratt. “The goal is to develop effective treatments and use psychedelics as one component within a larger therapeutic process.”
Patients participating in Sheppard Pratt’s studies undergo extensive screening and preparation before treatment. During dosing sessions, they are supported by highly trained clinicians. Afterward, they work to process and integrate their experiences into meaningful, lasting behavioral change.
This approach is especially important because psychedelic experiences can be deeply emotional and, at times, psychologically challenging.
“The risks are not always where people think they are,” says LaPratt. “The compounds themselves can be remarkably safe when appropriately screened and administered. Much of the responsibility lies in creating the right environment, ensuring ethical care, and providing skilled clinical support.”
Defining the Next Era of Care
As psychedelic therapies move closer to broader clinical availability, Aaronson believes psychiatry is approaching an important turning point. The next challenge will not simply be determining whether psychedelic compounds work. It will be understanding how to use them effectively, responsibly, and in ways that maximize long-term outcomes for patients.
For organizations like Sheppard Pratt, that means helping establish the standards, training, and clinical frameworks that will guide the field’s future.
“There is still a tremendous amount to learn,” Aaronson says. “But we are beginning to see possibilities for patients who have often exhausted many other options.”
For individuals living with chronic suicidal ideation and other severe psychiatric illnesses, those possibilities may represent something psychiatry has struggled to provide for decades: a new path forward.